Pharmacokinetic evaluation of desogestrel as a female contraceptive

@article{Grandi2014PharmacokineticEO,
  title={Pharmacokinetic evaluation of desogestrel as a female contraceptive},
  author={Giovanni Grandi and Angelo Cagnacci and Annibale Volpe},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2014},
  volume={10},
  pages={1 - 10}
}
Introduction: Desogestrel (DSG) is a third-generation 19-nortestosterone derivative progestogen. It is contained in many oral contraceptive preparations, both combined (COCs) to ethinyl-estradiol (EE) or alone in a progestin-only pill (POP). Its principal metabolite (etonogestrel, ETN) is the only progestin used for intravaginal combined contraception and one of the most used for subdermal hormonal contraception. Areas covered: This is a review of the available data on the pharmacokinetics of… 
Metabolic impact of combined hormonal contraceptives containing estradiol
TLDR
The preliminar parenteral use of E2 seems promising, both transdermal and vaginal, in particular after the introduction of a specific progestin with a high anti-ovulatory activity, like nestorone.
The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism
TLDR
A narrative review of the available data on the pharmacotherapy of NGM in combined hormonal contraceptives (CHCs) in terms of contraceptive efficacy, venous thromboembolism risk, safety, tolerability and bleeding patterns is reviewed.
Delivery of progestins via the subdermal versus the intrauterine route: comparison of the pharmacology and clinical outcomes
TLDR
Under normal circumstances, user satisfaction appeared marginally greater for intrauterine rather than subdermal progestin provision, however, after uterine events such as pregnancy or surgical evacuation of the uterus, implants performed better.
Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception
TLDR
The DRSP-only pill represents a real step forward in oral contraception with only progestins, even if the bleeding patterns during its use are still different to oestrogen-containing products (i.e. lower rates of scheduled bleedings and higher rate of amenorrhea).
Hormonal contraceptives: pharmacology tailored to women's health.
TLDR
Progress in the provision of new oral contraceptives has improved the risk/benefit ratio, by increasing benefits and reducing risks.
Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
TLDR
This phase 3 open-label study demonstrated that a 21/7-active COC regimen including 21days of DSG 150mcg/EE 20mcg and 7days of EE 10mcg was efficacious and well tolerated for pregnancy prevention.
Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle?
  • G. Grandi, F. Facchinetti, J. Bitzer
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2017
TLDR
The International Active Surveillance study ‘Safety of Contraceptives: role of Estrogens’ (INAS-SCORE) investigated the cardiovascular risks and the effectiveness associated with the use of the CHC containing E2V/DNG compared to other EE-based ones in a routine clinical setting.
A comprehensive review of hormonal and biological therapies for endometriosis: latest developments
TLDR
This review aims to give the reader a complete and updated overview of hormonal and biological therapies for the treatment of endometriosis, underlining the latest developments in this field of research.
Nature-inspired male contraceptive and spermicidal products
TLDR
This review aimed to evaluate the efficacy of natural products alternatives in the induction of male infertility (male contraception) and/or proceeding of spermicidal action (vaginal contraception), although, that concept may be contradictory or prohibited in some developing and well-developed countries due to low birth rate problems, traditional, and religious beliefs.
Hormonal contraception in women with endometriosis: a systematic review
  • G. Grandi, F. Barra, +4 authors F. Facchinetti
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2019
TLDR
CHCs and POCs are effective for the relief of endometriosis-related dysmenorrhoea, pelvic pain and dyspareunia, and improve QoL, with insufficient evidence, however, to reach definitive conclusions about the overall superiority of any particular hormonal contraceptive.
...
1
2
3
4
...

References

SHOWING 1-10 OF 62 REFERENCES
Drug safety evaluation of desogestrel
TLDR
Although DSG is efficacious in HRT, it may not represent the best choice due to the potential higher risk of breast cancer compared with progesterone or dydrogesterone.
Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study.
TLDR
The present data indicate that in contrast to OC use, vaginal contraception with the ring does not deteriorate SI, and the vaginal ring may represent an appropriate choice for long-term contraception in women at risk for developing diabetes mellitus or metabolic syndrome.
Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials.
TLDR
This report combines the data obtained in three multicenter efficacy studies with a new triphasic oral contraceptive combination containing desogestrel (DSG) and ethinyl estradiol (EE) to demonstrate thatTriphasic DSG/EE is an effective and acceptable triphasics oral contraceptive preparation with excellent cycle control and no significant physiologic effects.
Excretion and metabolism of desogestrel in healthy postmenopausal women
TLDR
Major metabolic routes found in the present study in postmenopausal women are in line with outcome of previous in vitro metabolism studies with human liver tissue (microsomes and postmitochondrial liver fractions) and intestinal mucosa.
Pharmacokinetics of Etonogestrel and Ethinylestradiol Released from a Combined Contraceptive Vaginal Ring
TLDR
Systemic exposure to etonogestrel was similar for Nuva ring® and the DSG/EE COC, whereas systemic exposure to ethinylestradiol with NuvaRing® was only approximately 50% of that for theDSG/ EE COC.
Seventy‐Five Microgram Desogestrel Minipill, A New Perspective in Estrogen‐Free Contraception
TLDR
The high effectiveness of the DSG minipill is attributable to an almost constant inhibition of ovulation, as shown by the absence of elevated progesterone circulating levels and inhibition of follicular growth in the vast majority of cycles studied.
Metabolic effects of implantable steroid contraceptives for women.
TLDR
The metabolic impact of progestin-only contraceptives is less than that of combined oral contraceptives, but additional empiric data from well-designed, well-implemented, and well-reported trials in women who are deemed to be at elevated risk for certain diseases including cardiovascular disease and diabetes are well served.
Types of progestogens in combined oral contraception: effectiveness and side-effects.
TLDR
Comparing currently available low-dose COCs containing ethinyl estradiol and different progestogens in terms of contraceptive effectiveness, cycle control, side effects and continuation rates suggests third-generation progestogenic COC's may be preferable to second-generation preparations with regard to bleeding patterns but further evidence is needed.
Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa.
TLDR
The results of this study indicate substantial first pass metabolism of desogestrel by the gut mucosa with evidence for the formation of the active metabolite.
Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial.
TLDR
It is confirmed that DSG, even when associated with low EE dose, decreases insulin sensitivity (SI), and EE/CMA does not deteriorate SI and induces a favorable lipid profile.
...
1
2
3
4
5
...